Whalesbook
Stock Ka 52-Week High Level!
Arre bhai, Apollo Hospitals Enterprise ke shares ne aaj ₹8,388 ka 52-week high level touch kar liya hai! Ye tezi isliye aayi kyuki March 2026 ko khatam hone wale fiscal fourth quarter mein company ka consolidated net profit 36% saal-dar-saal badh kar ₹529 crore ho gaya. Isi badhiya performance ki wajah se, announcement se pehle ke teen trading sessions mein stock 4% se zyada badh gaya. Company ke revenue from operations ne bhi solid growth dikhaya, jo 18.1% badh kar ₹6,605.5 crore ho gaya.
Q4 Ke Financial Highlights
Har business segment mein healthy growth ne Q4 ke results ko aur bhi accha bana diya. Healthcare services division ka revenue 17.25% badh kar ₹3,333.7 crore raha. Apollo Health and Lifestyle segments mein 24.2% ka revenue rise dekha gaya, jo ₹489.5 crore raha, jabki Apollo HealthCo ka revenue 20% badh kar ₹2,848.2 crore ho gaya. Poore fiscal year 2026 ke liye, consolidated net profit 34% badh kar ₹1,942 crore raha, aur revenue 16% badh kar ₹25,229 crore ho gaya. Company ka EBITDA bhi is quarter mein 31% saal-dar-saal badh kar ₹1,011 crore ho gaya.
Strategic Moves: Business Sell Kar Ke Expansion
Ek bada strategic move ye hai ki company ne apne fertility aur maternity businesses ko Cloudnine Hospitals ko ₹1,550 crore mein sell karne ka announce kiya hai. Apollo Hospitals combined entity mein ek minority stake maintain karegi. Is sale se jo paisa aayega, use diagnostics aur other digital platforms mein aur expansion ke liye use kiya jayega. Company ka aim hai ki next 12 se 18 mahine mein apne current 10,900+ beds ke base mein lagbhag 1,500 beds aur add karein. FY27 ke liye mid-teen revenue growth ka projection hai. Iske alawa, company ek composite scheme of arrangement ke through specific units ko demerge karne aur pharmacy distribution ko Apollo Healthtech Limited mein consolidate karne jaa rahi hai, jiska aim digital health growth aur operational efficiencies ko boost karna hai.
Analysts Kya Bol Rahe Hain?
Brokerage firms ne financial results par positive reaction diya hai. Macquarie Group ne notice kiya ki quarterly performance revenue, EBITDA, aur adjusted PAT ke estimates se zyada raha, aur EBITDA margin 15.3% raha. Motilal Oswal Financial Services ne Apollo HealthCo mein strong EBITDA growth aur margin expansion highlight kiya. Overall analyst sentiment kafi positive hai, jisme 28 buy recommendations, 1 hold, aur 1 sell hai. Average analyst target price lagbhag ₹8,801.97 hai, jo recent closing price se lagbhag 8.41% upside potential dikhata hai.
Valuation Snapshot
Apollo Hospitals ka current Price-to-Earnings (P/E) ratio May 20, 2026 tak lagbhag 63.40 hai, jo industry P/E of 62.02 se thoda zyada hai. Jabki trailing P/E of 61.71 (March 5, 2026 tak) premium valuation dikhata hai, forward P/E of 46.36 suggest karta hai ki analysts earnings growth expect kar rahe hain. Company ka P/E ratio fluctuate hua hai, March 2021 mein 206.8x aur March 2022 mein 57.3x tak gaya hai. Competition mein, Kovai Medical Center and Hospital Limited ka P/E ratio 24.9x hai. Lekin, Macquarie ne ₹5,700 ke target price ke saath 'Sell' rating maintain ki hai, jiske reasons healthcare services mein slower organic growth aur hospital network expansion mein challenges hain.
Regulatory Aur Corporate Updates
Company kuch structural changes kar rahi hai. National Company Law Tribunal dwara approve kiya gaya composite scheme of arrangement, pharmacy distribution aur digital health businesses ko consolidate karega. Iske alawa, Apollo Hospitals North Limited, Apollo Hospitals Enterprise Limited mein merge hone ja rahi hai, jo regulatory approvals ke baad hoga. Pharmacy aur digital health businesses ka demerger Q4 FY27 tak list ho sakta hai. CRISIL ne Apollo Hospitals ke long-term bank facilities ke liye 'AA+' rating aur 'Positive' outlook maintain kiya hai, jo company ki dominant market position aur strong financial profile ko highlight karta hai.
Future Prospects Aur Dividends
Apollo Hospitals FY27 ke liye mid-teen revenue growth forecast kar rahi hai. Board ne FY26 ke liye ₹10 per equity share ka final dividend recommend kiya hai, jo Annual General Meeting on August 25, 2026 ko shareholder approval ke baad hoga. Company ne full fiscal year 2026 ke liye consolidated net profit mein 34% ka increase bhi report kiya hai. Analysts accelerated growth ko lekar optimistic hain, aur predict kar rahe hain ki 2027 tak 19% annualised revenue growth hoga, jo industry growth rate 21% ke aas-paas hoga. Analysts ka consensus 12-month target price ₹7,800 se ₹8,500 ke beech hai, jo 'Buy' recommendation indicate karta hai, agar macro conditions stable rahein aur earnings consistent deliver ho.